Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Minerva Neuroscie (NERV)

Minerva Neuroscie (NERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Minerva Neuroscie 1500 DISTRICT AVE BURLINGTON MA 01803 USA

www.minervaneurosciences.com Employees: 8 P: 617-600-7373

Sector:

Medical

Description:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States.

Key Statistics

Overview:

Market Capitalization, $K 173,961
Enterprise Value, $K 152,501
Shares Outstanding, K 43,274
Annual Sales, $ 0 K
Annual Net Income, $ 1,440 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -2,740 K
EBIT, $ -14,630 K
EBITDA, $ -14,610 K
60-Month Beta -0.40
% of Insider Shareholders 10.40%
% of Institutional Shareholders 34.56%
Float, K 38,773
% Float 89.60%
Short Interest 359
Short Float 0.83%
Short Volume Ratio 0.41

Growth:

1-Year Return 75.55%
3-Year Return 139.29%
5-Year Return -80.52%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 101.28%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.36 on 11/05/25
Next Earnings Date 02/24/26
Earnings Per Share ttm -1.85
EPS Growth vs. Prev Qtr 16.28%
EPS Growth vs. Prev Year -112.12%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 06/21/22

NERV Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -41.35%
Return-on-Assets % -43.68%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow 19.43
Price/Book N/A
Book Value/Share 0.00
Interest Coverage -1.14
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar